PL1663970T3 - Inhibitory metaloproteinaz macierzy - Google Patents
Inhibitory metaloproteinaz macierzyInfo
- Publication number
- PL1663970T3 PL1663970T3 PL04765231T PL04765231T PL1663970T3 PL 1663970 T3 PL1663970 T3 PL 1663970T3 PL 04765231 T PL04765231 T PL 04765231T PL 04765231 T PL04765231 T PL 04765231T PL 1663970 T3 PL1663970 T3 PL 1663970T3
- Authority
- PL
- Poland
- Prior art keywords
- alkyl
- alkylaryl
- cor
- optionally substituted
- bond
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0321538.1A GB0321538D0 (en) | 2003-09-13 | 2003-09-13 | Therapeutically useful compounds |
| EP04765231A EP1663970B1 (en) | 2003-09-13 | 2004-09-10 | Matrix metalloproteinase inhibitors |
| PCT/EP2004/010319 WO2005026120A1 (en) | 2003-09-13 | 2004-09-10 | Matrix metalloproteinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1663970T3 true PL1663970T3 (pl) | 2009-04-30 |
Family
ID=29227079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04765231T PL1663970T3 (pl) | 2003-09-13 | 2004-09-10 | Inhibitory metaloproteinaz macierzy |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US7601729B2 (pl) |
| EP (3) | EP1663970B1 (pl) |
| JP (3) | JP2007505081A (pl) |
| KR (3) | KR20120007566A (pl) |
| CN (1) | CN1849306B (pl) |
| AT (2) | ATE413384T1 (pl) |
| AU (1) | AU2004272280C1 (pl) |
| BR (1) | BRPI0413791A (pl) |
| CA (1) | CA2538315C (pl) |
| CY (1) | CY1109400T1 (pl) |
| DE (2) | DE602004031991D1 (pl) |
| DK (1) | DK1663970T3 (pl) |
| ES (2) | ES2362954T3 (pl) |
| GB (1) | GB0321538D0 (pl) |
| HK (1) | HK1092141A1 (pl) |
| HR (1) | HRP20080668T3 (pl) |
| IL (1) | IL173305A (pl) |
| IS (2) | IS2622B (pl) |
| MA (1) | MA28039A1 (pl) |
| MX (1) | MXPA06002458A (pl) |
| NO (1) | NO20060540L (pl) |
| NZ (2) | NZ545211A (pl) |
| PL (1) | PL1663970T3 (pl) |
| PT (1) | PT1663970E (pl) |
| RU (2) | RU2370488C2 (pl) |
| SG (1) | SG145685A1 (pl) |
| SI (1) | SI1663970T1 (pl) |
| WO (1) | WO2005026120A1 (pl) |
| ZA (1) | ZA200602070B (pl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0321538D0 (en) * | 2003-09-13 | 2003-10-15 | Glaxo Group Ltd | Therapeutically useful compounds |
| KR101274309B1 (ko) * | 2005-02-22 | 2013-06-13 | 랜박시 래보러터리스 리미티드 | 천식 및 기타 질병의 치료를 위한 기질 메탈로프로테나제저해제로서 5-페닐-펜탄산 유도체 |
| CA2661299A1 (en) * | 2006-08-22 | 2008-02-28 | Ranbaxy Laboratories Limited | Beta -hydroxy-and amino-substituted carboxylic acids as matrix metalloproteinase inhibitors |
| AU2013200728B2 (en) * | 2006-08-22 | 2014-12-18 | Sun Pharmaceutical Industries Limited | Matrix metalloproteinase inhibitors |
| ES2569660T3 (es) | 2007-06-08 | 2016-05-12 | Mannkind Corporation | Inhibidores de la IRE-1alfa |
| FR2949463B1 (fr) * | 2009-08-26 | 2011-09-16 | Commissariat Energie Atomique | Inhibiteurs de mmp |
| WO2012014114A1 (en) | 2010-07-30 | 2012-02-02 | Ranbaxy Laboratories Limited | Matrix metalloproteinase inhibitors |
| AU2011306396A1 (en) | 2010-09-24 | 2013-05-02 | Ranbaxy Laboratories Limited | Matrix metalloproteinase inhibitors |
| US20160045463A1 (en) | 2012-11-28 | 2016-02-18 | Universidad De Salamanca | Use of metalloprotease inhibitors in the treatment of polycystic liver diseases |
| PT3413892T (pt) | 2016-02-12 | 2022-05-30 | Cytokinetics Inc | Derivados de tetra-hidroisoquinolina |
| CN110769866B (zh) * | 2017-06-13 | 2022-07-29 | 爱惜康有限责任公司 | 具有可控愈合的外科缝合器 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4102024A1 (de) * | 1991-01-24 | 1992-07-30 | Thomae Gmbh Dr K | Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| WO1995029901A1 (en) * | 1994-04-28 | 1995-11-09 | Uniroyal Chemical Company, Inc. | Fungicidal azole derivatives |
| EP0865431A2 (en) * | 1995-12-06 | 1998-09-23 | Astra Pharmaceuticals Limited | Compounds |
| TR199802104T2 (xx) | 1996-04-19 | 2000-09-21 | Akzo Nobel N.V. | �kame edilmi� benzilaminler ve bunlar�n depresyonla ili�kili kullan�m�. |
| CO4990925A1 (es) * | 1996-05-15 | 2000-12-26 | Bayer Corp | Acidos oxibutiricos sustituidos como inhibidores de la metaloproteasa de matriz |
| US5789605A (en) | 1996-12-03 | 1998-08-04 | Trustees Of The University Of Pennsylvania | Synthetic techniques and intermediates for polyhydroxy, dienyl lactones and mimics thereof |
| US6242616B1 (en) | 1996-12-03 | 2001-06-05 | The Trustees Of The University Of Pennsylvania | Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives |
| US6096904A (en) | 1996-12-03 | 2000-08-01 | The Trustees Of The University Of Pennsylvania | Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives |
| US6870058B2 (en) | 1996-12-03 | 2005-03-22 | The Trustees Of The University Of Pennsylvania | Compounds which mimic the chemical and biological properties of discodermolide |
| US20050065353A1 (en) | 1996-12-03 | 2005-03-24 | Smith Amos B. | Synthetic techniques and intermediates for polyhydroxy dienyl lactones and mimics thereof |
| US5804581A (en) * | 1997-05-15 | 1998-09-08 | Bayer Corporation | Inhibition of matrix metalloproteases by substituted phenalkyl compounds |
| US6608052B2 (en) * | 2000-02-16 | 2003-08-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
| CA2490819A1 (en) * | 2001-04-13 | 2002-10-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
| AU2003261319A1 (en) * | 2002-08-01 | 2004-02-23 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme |
| CA2505299C (en) * | 2002-11-19 | 2012-11-13 | Galderma Research & Development, S.N.C. | Novel biaromatic compunds which activate ppary type receptors, and use therof in cosmetic or pharmaceutical compositions |
| GB0312654D0 (en) * | 2003-06-03 | 2003-07-09 | Glaxo Group Ltd | Therapeutically useful compounds |
| GB0314488D0 (en) | 2003-06-20 | 2003-07-23 | Glaxo Group Ltd | Therapeutically useful compounds |
| GB0319069D0 (en) | 2003-08-14 | 2003-09-17 | Glaxo Group Ltd | Therapeutically useful compounds |
| GB0321538D0 (en) * | 2003-09-13 | 2003-10-15 | Glaxo Group Ltd | Therapeutically useful compounds |
| KR101274309B1 (ko) | 2005-02-22 | 2013-06-13 | 랜박시 래보러터리스 리미티드 | 천식 및 기타 질병의 치료를 위한 기질 메탈로프로테나제저해제로서 5-페닐-펜탄산 유도체 |
| CA2661299A1 (en) | 2006-08-22 | 2008-02-28 | Ranbaxy Laboratories Limited | Beta -hydroxy-and amino-substituted carboxylic acids as matrix metalloproteinase inhibitors |
-
2003
- 2003-09-13 GB GBGB0321538.1A patent/GB0321538D0/en not_active Ceased
-
2004
- 2004-09-10 ES ES08163972T patent/ES2362954T3/es active Active
- 2004-09-10 US US10/571,443 patent/US7601729B2/en not_active Expired - Fee Related
- 2004-09-10 EP EP04765231A patent/EP1663970B1/en active Active
- 2004-09-10 MX MXPA06002458A patent/MXPA06002458A/es active IP Right Grant
- 2004-09-10 AU AU2004272280A patent/AU2004272280C1/en not_active Ceased
- 2004-09-10 NZ NZ545211A patent/NZ545211A/en not_active IP Right Cessation
- 2004-09-10 CN CN200480026229.7A patent/CN1849306B/zh not_active Expired - Fee Related
- 2004-09-10 PT PT04765231T patent/PT1663970E/pt unknown
- 2004-09-10 WO PCT/EP2004/010319 patent/WO2005026120A1/en active Application Filing
- 2004-09-10 SI SI200431008T patent/SI1663970T1/sl unknown
- 2004-09-10 DK DK04765231T patent/DK1663970T3/da active
- 2004-09-10 ES ES04765231T patent/ES2314436T3/es active Active
- 2004-09-10 EP EP10176905A patent/EP2295408A1/en not_active Withdrawn
- 2004-09-10 CA CA2538315A patent/CA2538315C/en not_active Expired - Fee Related
- 2004-09-10 BR BRPI0413791-4A patent/BRPI0413791A/pt not_active IP Right Cessation
- 2004-09-10 AT AT04765231T patent/ATE413384T1/de active
- 2004-09-10 DE DE602004031991T patent/DE602004031991D1/de active Active
- 2004-09-10 SG SG200805432-2A patent/SG145685A1/en unknown
- 2004-09-10 PL PL04765231T patent/PL1663970T3/pl unknown
- 2004-09-10 KR KR1020127000264A patent/KR20120007566A/ko not_active Application Discontinuation
- 2004-09-10 RU RU2006106850/04A patent/RU2370488C2/ru not_active IP Right Cessation
- 2004-09-10 JP JP2006525794A patent/JP2007505081A/ja active Pending
- 2004-09-10 AT AT08163972T patent/ATE502922T1/de not_active IP Right Cessation
- 2004-09-10 KR KR1020067005114A patent/KR20060120648A/ko active Search and Examination
- 2004-09-10 EP EP08163972A patent/EP2042488B1/en active Active
- 2004-09-10 DE DE602004017622T patent/DE602004017622D1/de active Active
- 2004-09-10 KR KR1020137014317A patent/KR20130079628A/ko not_active Application Discontinuation
- 2004-09-10 NZ NZ573479A patent/NZ573479A/en not_active IP Right Cessation
-
2006
- 2006-01-23 IL IL173305A patent/IL173305A/en not_active IP Right Cessation
- 2006-01-26 IS IS8268A patent/IS2622B/is unknown
- 2006-02-02 NO NO20060540A patent/NO20060540L/no not_active Application Discontinuation
- 2006-03-10 ZA ZA200602070A patent/ZA200602070B/en unknown
- 2006-03-14 MA MA28873A patent/MA28039A1/fr unknown
- 2006-11-15 HK HK06112572.5A patent/HK1092141A1/xx not_active IP Right Cessation
-
2008
- 2008-11-07 US US12/266,767 patent/US8263602B2/en not_active Expired - Fee Related
- 2008-11-26 RU RU2008146479/04A patent/RU2008146479A/ru not_active Application Discontinuation
- 2008-12-19 HR HR20080668T patent/HRP20080668T3/xx unknown
-
2009
- 2009-01-27 CY CY20091100090T patent/CY1109400T1/el unknown
- 2009-08-19 IS IS8843A patent/IS8843A/is unknown
- 2009-09-01 US US12/551,892 patent/US8343986B2/en not_active Expired - Fee Related
-
2011
- 2011-06-14 JP JP2011132261A patent/JP2011231118A/ja not_active Withdrawn
-
2012
- 2012-01-25 JP JP2012012663A patent/JP2012107031A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20080668T3 (en) | Matrix metalloproteinase inhibitors | |
| ATE362910T1 (de) | Matrix metalloprotease inhibitoren | |
| IL154893A0 (en) | Aliphatic nitrogen-containing cyclic compounds, methods for the preparation thereof and pharmaceutical compositions containing the same | |
| HUP0201475A2 (hu) | Heteroarilamidin-, metilamidin- és guanidinszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények | |
| EA200300044A1 (ru) | Новые замещенные фталиды, способ их получения и содержащие их фармацевтические композиции | |
| DE3883140D1 (de) | Imidazo(2,1-b)benzothiazole und ihre saeureadditionssalze, verfahren und zwischenprodukte zu ihrer herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zubereitungen. | |
| YU74201A (sh) | Nova sinteza prstena piperazina | |
| DK1010698T3 (da) | Hidtil ukendte derivater af 1,2-dithiolan, fremgangsmåde til fremstiling deraf og farmaceutiske sammensætninger indeholdende dem | |
| ATE239021T1 (de) | Metalloproteaseinhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen | |
| WO2002074764A3 (en) | Piperazine derivatives and their use as 5-ht1b ligands | |
| DK1188752T3 (da) | Fremgangsmåde til fremstilling af substitueret alkylaminderivat | |
| GB1183442A (pl) | ||
| ES2058182T3 (es) | Analogos de mitomicina. un procedimiento para su preparacion y composiciones farmaceuticas. |